How Oral Estrogen Impacts Cardiovascular Risk After Menopause
A review of the impact of oral estrogen therapy on risk for cardiovascular disease after menopause.
A review of the impact of oral estrogen therapy on risk for cardiovascular disease after menopause.
Investigators compared sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4is) in a propensity-score matched group of patients with gout and type 2 diabetes.
A study was conducted to determine the effect of SGLT2 inhibitors on embolic events in patients with atrial fibrillation and diabetes.
Although testosterone therapy was significantly associated with a higher risk for pulmonary embolism.
A study was conducted to determine the effect of aspirin on 28-day mortality following admission to the intensive care unit.
This Swedish population-based study has the largest sample size to date exploring these associations.
The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.
Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators.
Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.
Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.